Download Free Sample
captcha refresh

Thyrogen and Biosimilar Market Size, Share, Growth, and Industry Analysis, By Type (Brand, Biosimilar), By Application (Hospital, Pharmacy, Other), Regional Insights and Forecast to 2035

Thyrogen and Biosimilar Market Overview

The global thyrogen and biosimilar market size is anticipated to reach USD 527.6 million in 2026 and is projected to attain USD 1901.53 million by 2035, expanding at a 15.31% CAGR. Market expansion is supported by increasing differentiated thyroid cancer monitoring, wider use of recombinant human thyroid-stimulating hormone, growing radioactive iodine procedures, and demand for diagnostic approaches that allow patients to continue thyroid hormone replacement. Thyrogen remains the established thyrotropin alfa reference product, while recombinant alternatives are strengthening future competitive potential.

The United States represents a major market for recombinant human thyroid-stimulating hormone because of established thyroid cancer surveillance infrastructure, specialist endocrinology networks, nuclear medicine capabilities, and access to biologic medicines. Thyrogen is administered as 0.9 mg intramuscular injections on 2 consecutive days for approved diagnostic and remnant-ablation applications. The product enables patients to remain on thyroid hormone replacement rather than undergoing prolonged hormone withdrawal before selected procedures. Approximately 44,000 new thyroid cancer cases are expected annually in the country, supporting continued demand for follow-up testing, thyroglobulin measurement, radioactive iodine imaging, and differentiated thyroid cancer management.

Global Thyrogen and Biosimilar Market Size,

Key Findings

  • Market Size and Forecast: The thyrogen and biosimilar marketreaches USD 527.6 million in 2026 and USD 1901.53 million by 2035, recording 15.31% CAGR.
  • Type Leadership: Brand products hold 76% market share, supported by established physician confidence, regulatory approvals, clinical familiarity, and consistent recombinant hormone availability.
  • Application Leadership: Hospital applications account for 56% market share as specialist cancer centers coordinate thyroglobulin testing, radioactive iodine procedures, monitoring, and injectable administration.
  • Key Company Landscape: Sanofi and Sato Pharmaceutical support market development through established Thyrogen commercialization, regional distribution capabilities, physician engagement, and specialized endocrine medicine expertise.
  • Fastest Growing Region: North America holds 38% market share, strengthened by thyroid cancer surveillance, nuclear medicine infrastructure, specialist access, and biologic treatment adoption.
  • Key Trends: Recombinant hormone competition is increasing as long-acting technologies advance and new rhTSH products demonstrate diagnostic concordance above 88% in clinical evaluation.

The thyrogen and biosimilar market is increasingly shaped by efforts to improve differentiated thyroid cancer follow-up without requiring thyroid hormone withdrawal. Recombinant human thyroid-stimulating hormone supports thyroglobulin testing and radioactive iodine imaging while allowing selected patients to continue hormone replacement, improving procedural convenience and reducing exposure to temporary hypothyroid symptoms. Thyrogen is supplied at a 0.9 mg administered dose, and treatment preparation typically uses 2 intramuscular injections separated by 24 hours. This established protocol has encouraged endocrinologists, oncologists, nuclear medicine specialists, and hospitals to integrate recombinant stimulation into structured surveillance pathways. Product development is also shifting toward alternative recombinant molecules designed to improve pharmacokinetic duration, manufacturing efficiency, consistency, and patient scheduling.

A second major trend is the emergence of recombinant TSH competition outside the historically concentrated branded market. New biologic development programs are targeting improved accessibility and regional supply security, particularly in Asian pharmaceutical markets. A recently approved recombinant human thyrotropin beta program reported 88.2% concordance for whole-body scanning compared with thyroid hormone withdrawal in clinical evaluation, highlighting the possibility of additional treatment choices. Researchers are also evaluating long-acting recombinant TSH designs using technologies intended to extend biological activity. These developments are increasing interest in biosimilar-style manufacturing capabilities, advanced cell-line production, protein characterization, glycosylation control, pharmacodynamic testing, and biologic comparability strategies within the thyrogen and biosimilar market.

Market Dynamics

DRIVER

"Growing use of recombinant thyroid stimulation in differentiated thyroid cancer management"

Increasing clinical emphasis on convenient surveillance and radioactive iodine preparation is a major driver of the thyrogen and biosimilar market. Recombinant human thyroid-stimulating hormone allows appropriate patients to remain on thyroid hormone therapy while undergoing stimulated thyroglobulin testing, radioactive iodine imaging, or thyroid remnant ablation. Thyrogen uses a 0.9 mg intramuscular administration followed by a second equivalent dose after 24 hours, creating a defined treatment pathway that can be coordinated through hospitals and specialist clinics. Thyroid cancer is among the more frequently diagnosed endocrine malignancies, and differentiated forms represent the dominant clinical group. The requirement for long-term surveillance following thyroidectomy generates continuing demand for recombinant stimulation, laboratory testing, imaging, specialist consultation, and nuclear medicine procedures.

Drivers Impact Analysis*

Market driver CAGR contribution impact (%) Impact level (2026-2028) Impact level (2029-2031) Impact level (2032-2035)
Rising prevalence of differentiated thyroid cancer and expanding post-treatment surveillance 5.20% High High High
Growing adoption of recombinant human thyroid-stimulating hormone in diagnostic and therapeutic preparation 4.30% High High High
Increasing development and commercialization of biosimilar and alternative recombinant TSH products 3.70% Medium High High
Expansion of nuclear medicine infrastructure and radioactive iodine treatment capabilities 3.10% Medium High High
Improving biologic manufacturing technology and wider access to specialty pharmaceutical treatment 2.70% Medium Medium High
Others 1.80% Low Low Medium

RESTRAINT

"High biologic development complexity and limited competitive product availability"

The thyrogen and biosimilar market faces restraints related to biologic manufacturing complexity, specialist administration requirements, regulatory expectations, and limited alternative recombinant products in several major healthcare systems. Thyrotropin alfa is a glycoprotein manufactured through recombinant technology, requiring controlled cell culture, purification, potency testing, protein characterization, and quality assurance. Small differences in manufacturing processes can influence molecular characteristics and create additional development requirements for prospective competitors. Thyrogen is also supplied as an injectable prescription product and requires coordination between physicians, laboratories, nuclear medicine departments, and patients. Its 2-dose administration schedule introduces logistical considerations that are different from ordinary oral endocrine therapy. These technical and clinical barriers can slow competitor entry and restrict rapid expansion of affordable biosimilar-style alternatives.

Restraints Impact Analysis*

Market restraint CAGR contribution impact (%) Impact level (2026-2028) Impact level (2029-2031) Impact level (2032-2035)
High cost and complexity of recombinant biologic development and manufacturing -2.10% High High Medium
Stringent regulatory, clinical comparability, and biosimilar approval requirements -1.55% High Medium Medium
Limited availability of approved alternative recombinant TSH products in several markets -1.14% Medium Medium Low
Others -0.70% Low Low Low

OPPORTUNITY

"Expansion of recombinant TSH alternatives and long-acting biologic technologies"

A significant opportunity exists in developing alternative recombinant human TSH products capable of expanding access beyond established branded therapy. Growing biologics expertise in Asia Pacific is encouraging manufacturers to explore recombinant proteins, improved expression systems, optimized purification platforms, and localized manufacturing. Recent clinical development has demonstrated that alternative rhTSH products can achieve diagnostic performance approaching conventional preparation approaches. One recombinant thyrotropin beta program produced whole-body scanning concordance of 88.2%, indicating meaningful potential for broader clinical competition. Long-acting research platforms also create opportunities to modify pharmacokinetic behavior and reduce administration burden. Companies that successfully combine reproducible protein quality, dependable supply, regulatory compliance, competitive pricing, and strong hospital partnerships can address unmet demand in emerging markets and strengthen the future thyrogen and biosimilar market.

CHALLENGE

"Demonstrating clinical comparability and maintaining consistent recombinant protein quality"

One of the principal challenges facing the thyrogen and biosimilar market is establishing robust clinical and analytical evidence for alternative recombinant products. Thyroid-stimulating hormone is biologically active through receptor-mediated mechanisms, meaning manufacturers must demonstrate appropriate structure, receptor activity, purity, potency, and pharmacodynamic performance. Production typically depends on mammalian expression technology, including Chinese hamster ovary cell systems used in recombinant biologic manufacturing. Developers must also address immunogenicity evaluation, glycosylation consistency, storage stability, batch comparability, and clinically meaningful endpoints. New entrants compete against an established reference medicine with decades of physician familiarity. Consequently, market penetration requires more than lower pricing. Successful competitors must demonstrate dependable quality, regulatory credibility, clinical effectiveness, product availability, and confidence among endocrinologists and nuclear medicine specialists.

Thyrogen and Biosimilar Market Segmentation

The thyrogen and biosimilar market is segmented by type into brand and biosimilar products and by application into hospital, pharmacy, and other channels. Type segmentation reflects differences in product maturity, regulatory positioning, physician familiarity, supply availability, and competitive strategies. Application segmentation describes where recombinant thyroid-stimulating hormone is primarily obtained, administered, or coordinated for thyroid cancer management. Hospitals remain especially important because stimulated thyroglobulin testing and radioactive iodine procedures often require multidisciplinary medical supervision. Pharmacy distribution supports scheduled access to prescribed injectable products, while other applications include specialty clinics, nuclear medicine facilities, endocrine centers, and selected ambulatory healthcare settings.

Global Thyrogen and Biosimilar Market Size, 2035

By Type

Based on type the global market can be categorized into brand and biosimilar.

  • Brand: The brand segment accounts for 76% of the thyrogen and biosimilar market. Demand is supported by the established clinical position of Thyrogen, physician familiarity, long-standing regulatory authorization, predictable dosing, and integration into differentiated thyroid cancer follow-up protocols. The branded product benefits from specialist awareness among endocrinologists, oncologists, surgeons, and nuclear medicine teams. Its role in stimulated thyroglobulin testing and radioactive iodine procedures has created a strong installed clinical presence. Continued availability across major healthcare systems supports brand leadership, although prospective recombinant competitors are expected to increase pressure on pricing, supply strategy, and regional positioning.
  • Biosimilar: The biosimilar segment represents 24% of the thyrogen and biosimilar market under the report's broader competitive classification for alternative and follow-on recombinant TSH products. Growth potential is associated with expanding biologic production expertise, increasing demand for cost-efficient recombinant medicines, and development of new thyrotropin candidates. Manufacturers are focusing on expression efficiency, protein characterization, receptor activity, pharmacodynamic performance, and reproducible manufacturing. Competitive opportunities are particularly significant in markets seeking greater local supply security. Regulatory classification can vary by product and jurisdiction, so alternative recombinant TSH therapies are not automatically considered formal biosimilars unless approved through the applicable biosimilar pathway.

By Application

Based on application the global market can be categorized into hospital, pharmacy and other.

  • Hospital: Hospitals account for 56% of the thyrogen and biosimilar market because recombinant TSH use is closely linked to specialist thyroid cancer care. Hospitals provide endocrinology consultation, laboratory testing, radioactive iodine administration, nuclear medicine imaging, oncology support, and monitoring within coordinated clinical pathways. The requirement for intramuscular administration and carefully scheduled diagnostic procedures supports institutional use. Large tertiary centers also manage patients following total or near-total thyroidectomy, creating recurring demand for stimulated thyroglobulin assessment and imaging. Hospital formularies therefore remain critical to product adoption, procurement negotiations, reimbursement management, and physician familiarity with recombinant thyroid-stimulating hormone products.
  • Pharmacy: Pharmacy applications hold 31% market share and support access to prescribed recombinant thyroid-stimulating hormone through specialty distribution and coordinated treatment programs. Specialty pharmacies can assist with prescription processing, reimbursement documentation, cold-chain handling, delivery scheduling, and patient access services. This channel is particularly important where biologic products are obtained before planned hospital or outpatient administration. Pharmacy involvement can reduce administrative complexity by coordinating with physicians and insurers while ensuring product availability near scheduled radioactive iodine or diagnostic appointments. As additional recombinant products reach commercial markets, pharmacies may become more influential in formulary substitution, benefit management, product education, and distribution efficiency.
  • Other: Other applications represent 13% of the thyrogen and biosimilar market and include specialist endocrine clinics, nuclear medicine facilities, oncology centers, outpatient diagnostic settings, and selected ambulatory care providers. These facilities support patients requiring structured follow-up after thyroid cancer surgery but may operate independently from larger hospital systems. Demand depends on local clinical infrastructure, availability of radioactive iodine services, specialist expertise, and reimbursement arrangements. Dedicated thyroid centers can streamline treatment planning by coordinating hormone stimulation, thyroglobulin testing, imaging, and follow-up consultations. Expansion of outpatient specialty medicine may gradually increase this segment's importance as healthcare systems decentralize selected cancer surveillance procedures.

Thyrogen and Biosimilar Market Regional Outlook

The thyrogen and biosimilar market demonstrates different adoption patterns according to thyroid cancer diagnosis, specialist availability, healthcare expenditure, recombinant biologic access, nuclear medicine capacity, and regulatory frameworks. Mature healthcare systems show stronger uptake of established recombinant TSH protocols, while emerging regions offer opportunities for alternative biologics and localized production. North America maintains the largest share, followed by Europe and Asia Pacific. Middle East & Africa and Rest of the World markets remain smaller but are benefiting from greater access to specialty oncology and endocrine services.

Global Thyrogen and Biosimilar Market Share, by Type 2035

  • North America:

North America holds 38% of the thyrogen and biosimilar market, supported by established differentiated thyroid cancer surveillance protocols and widespread access to specialist endocrinology services. The United States leads regional consumption because major medical centers combine thyroid surgery, thyroglobulin testing, nuclear medicine imaging, and radioactive iodine treatment. Recombinant stimulation is particularly relevant where physicians seek to avoid extended thyroid hormone withdrawal before eligible diagnostic or therapeutic procedures.

The region benefits from sophisticated biologic distribution networks, specialty pharmacies, reimbursement infrastructure, and experienced hospital systems. Thyrogen maintains an established regulatory and clinical position in the United States, strengthening physician familiarity. Approximately 44,000 new thyroid cancer cases annually create a substantial patient base requiring initial treatment and subsequent monitoring. Future competitive opportunities center on biologic accessibility, payer management, reliable supply, specialist education, and potential entry of alternative recombinant thyroid-stimulating hormone products.

  • Europe:

Europe represents 27% of the thyrogen and biosimilar market and benefits from mature oncology networks, national healthcare systems, and extensive nuclear medicine infrastructure. Germany, France, Italy, Spain, and the United Kingdom contribute materially to recombinant thyroid-stimulating hormone demand. Thyrogen has an established European regulatory history and remains used for differentiated thyroid cancer follow-up and selected radioactive iodine preparation. Centralized treatment guidelines and specialist referral pathways support consistent clinical utilization.

European demand is influenced by cost-effectiveness assessment, hospital procurement policies, biologic reimbursement, and evolving thyroid cancer management practices. The product contains thyrotropin alfa and is supplied as a 0.9 mg formulation for intramuscular use. Growing acceptance of biosimilars across other therapeutic categories may provide a favorable environment for future recombinant TSH competitors if developers establish regulatory comparability and dependable manufacturing. Procurement competition and regional health-budget controls are expected to influence future market positioning.

  • Asia Pacific:

Asia Pacific accounts for 23% of the thyrogen and biosimilar market and presents strong long-term competitive potential because of expanding biologic manufacturing capacity, improving cancer diagnostics, and increasing access to nuclear medicine. China and Japan are important markets, while South Korea contributes advanced recombinant biologic research capabilities. Rising specialist infrastructure is increasing the number of institutions capable of integrating recombinant thyroid stimulation into post-thyroidectomy surveillance workflows.

China is becoming particularly important for alternative recombinant TSH development. A domestically developed recombinant human thyrotropin beta product demonstrated 88.2% whole-body scanning concordance in pivotal clinical evaluation, providing evidence that regional innovation can challenge historical product concentration. Japan also has established experience with recombinant TSH use and specialty pharmaceutical distribution. Increasing domestic biotechnology investment, manufacturing localization, hospital expansion, and regulatory support for innovative biologics are strengthening Asia Pacific's role in the competitive landscape.

  • Middle East & Africa:

Middle East & Africa holds 7% of the thyrogen and biosimilar market. Demand is concentrated in countries with developed tertiary healthcare systems, particularly where comprehensive oncology, endocrinology, and nuclear medicine services are available. Gulf healthcare markets are investing in specialized cancer centers and diagnostic capacity, increasing opportunities for recombinant biologics used in thyroid cancer surveillance. Access remains uneven because specialized procedures require trained professionals and supporting laboratory infrastructure.

Regional growth potential depends on improving biologic distribution, specialist training, reimbursement availability, and reliable cold-chain logistics. South Africa and major Gulf markets provide important access points for advanced endocrine medicines. Thyroid cancer represents an important endocrine oncology indication, but recombinant TSH adoption remains more selective than in mature North American and European healthcare systems. Expansion of private hospitals, oncology programs, and imported biologic availability can progressively improve market penetration.

  • Rest of the World:

Rest of the World represents 5% of the thyrogen and biosimilar market, covering Latin America and smaller emerging healthcare markets. Brazil, Mexico, Argentina, and selected advanced medical centers elsewhere contribute demand through thyroid cancer surgery, endocrinology services, diagnostic imaging, and radioactive iodine treatment. Access to recombinant TSH remains concentrated in major urban hospitals because specialist administration, biologic procurement, and reimbursement conditions can limit broader utilization.

Market development is associated with improving cancer detection, wider insurance coverage, private healthcare investment, and increased availability of specialty pharmaceuticals. Thyrogen requires 2 planned intramuscular administrations in its standard preparation regimen, creating logistical needs that favor organized treatment centers. Future alternative recombinant products could improve regional competition where pricing remains an access barrier. Distributor partnerships and local regulatory approvals will be important for manufacturers seeking stronger participation across these emerging markets.

KEY INDUSTRY PLAYERS

The thyrogen and biosimilar market has historically remained concentrated because recombinant thyroid-stimulating hormone requires specialized biologic manufacturing and extensive regulatory evidence. Sanofi maintains a strong position through Thyrogen, established physician familiarity, regulatory presence, patient-support infrastructure, and global specialty medicine distribution. Sato Pharmaceutical has contributed to regional commercialization and thyroid-related pharmaceutical access, particularly through its historical involvement with Thyrogen in Japan. Competitive strategies increasingly include localized biologic manufacturing, regulatory partnerships, clinical validation, specialist education, and licensing arrangements. Emerging developers are focusing on recombinant alternatives, long-acting molecules, improved production systems, and regional commercialization. Partnerships with hospitals, distributors, testing laboratories, and nuclear medicine centers remain important for sustainable positioning.

List of Top Thyrogen and Biosimilar Companies

  • Sanofi
  • Sato Pharmaceutical

MARKET LEADERSHIP MATRIX

2×2 Matrix View Low to Medium Business Strength High Business Strength
High Future Growth Potential Growth Challengers: • Sato Pharmaceutical Leaders: • Sanofi

List of Top 2 Companies Market Share

  • Sanofi holds 68% share through established Thyrogen commercialization, broad regulatory presence, physician familiarity, and distribution.
  • Sato Pharmaceutical holds 12% share through regional commercialization experience, specialist positioning, and established pharmaceutical distribution.

Leader Insights

  • Sanofi: Paul Hudson, Chief Executive Officer at the time of publication, emphasized that expanding investment in emerging biotechnology and digital health companies would accelerate the development of next-generation therapies and strengthen partnerships across the healthcare ecosystem. His comments highlight strategic investment in pharmaceutical innovation and future commercialization opportunities, although they do not specifically address thyrotropin alfa or biosimilars. (Published: September 24, 2025 | Source: https://www.sanofi.com/)
  • Sato Pharmaceutical: Seiichi Sato, President and CEO, highlighted expanding healthcare demand, pharmaceutical innovation, international partnerships, and investments in drug discovery capabilities as important priorities for the company's future development. His statement emphasizes geographic expansion and collaboration with research institutions, although it does not specifically discuss the thyrogen and biosimilar market. The official executive message references Japan's 2025 healthcare policy, but its exact publication date is not stated. (Published: Date not specified | Source: https://www.sato-seiyaku.co.jp/)

Investment Analysis and Opportunities

Investment opportunities in the thyrogen and biosimilar market are increasingly connected to recombinant protein manufacturing, local biologic production, clinical comparability programs, and broader access to differentiated thyroid cancer care. The relatively concentrated competitive environment creates opportunities for developers capable of producing high-quality recombinant TSH while meeting strict potency, purity, glycosylation, immunogenicity, and stability requirements. A recombinant competitor demonstrating 88.2% whole-body scanning concordance illustrates the growing technical feasibility of additional products. Investors are consequently examining companies with expertise in mammalian cell culture, protein engineering, biologic analytical testing, contract manufacturing, and specialty pharmaceutical commercialization. Manufacturing scale and regulatory execution remain decisive because complex injectable biologics require significant quality-control infrastructure.

Additional opportunities are emerging through long-acting molecules, treatment-scheduling improvements, regional licensing, specialty pharmacy programs, and collaborations with nuclear medicine centers. Research using anti-serum albumin Fab-associated technology demonstrates industry interest in extending recombinant TSH biological activity beyond conventional formulations. Commercial potential is strongest where developers can reduce treatment burden while maintaining receptor activity and dependable diagnostic performance. Asia Pacific offers particularly attractive investment conditions because domestic biologic companies are expanding research capability and manufacturing capacity. Investors can also target cold-chain distribution, hospital procurement support, diagnostic coordination, and patient-access programs. Partnerships between biotechnology developers and established commercial pharmaceutical companies can accelerate registration, physician engagement, reimbursement access, and geographic expansion.

New Product Development

New product development in the thyrogen and biosimilar market is centered on alternative recombinant TSH molecules, longer-acting formulations, manufacturing optimization, and improved clinical convenience. Developers are investigating protein-engineering approaches intended to increase circulating activity while preserving TSH receptor stimulation. Long-acting SAFA-TSH research has demonstrated the feasibility of combining recombinant TSH with albumin-binding technology to modify pharmacokinetic behavior. Commercial innovation is also advancing in China, where recombinant human thyrotropin beta has entered the market following clinical evaluation. The product achieved 90.4% concordance for stimulated thyroglobulin assessment in its pivotal program. Future innovation will focus on dosing efficiency, biosafety, analytical comparability, production consistency, and broader regional accessibility.

Recent Developments

  • September 2026: Zelgen Biopharmaceuticals advanced a new-indication application for recombinant human thyrotropin beta, expanding development toward radioactive iodine treatment preparation and strengthening the product's potential role across differentiated thyroid cancer management pathways.
  • January 2026: Zelgen Biopharmaceuticals received regulatory approval for its self-developed recombinant human thyroid-stimulating hormone injection, establishing an additional rhTSH option designed to support postoperative assessment and surveillance of differentiated thyroid cancer patients.
  • January 2026: HyQure supported a recombinant human thyroid-stimulating hormone commercialization program through biologic safety testing capabilities, including viral clearance assessment and development services intended to strengthen large-molecule registration and manufacturing readiness.

Report Coverage

The thyrogen and biosimilar market report evaluates product adoption, recombinant thyroid-stimulating hormone technology, competitive positioning, clinical applications, development trends, investment opportunities, and regional market conditions. The analysis covers brand and biosimilar classifications together with hospital, pharmacy, and other application channels. Brand products account for 76% of the analyzed type landscape, reflecting the established clinical position of reference recombinant therapy. The report examines North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World, considering thyroid cancer surveillance infrastructure, biologic accessibility, specialist care, nuclear medicine capabilities, manufacturing development, and regulatory conditions. Competitive coverage includes Sanofi and Sato Pharmaceutical alongside emerging recombinant TSH development activity, product innovation, investment priorities, clinical technology, distribution strategy, and recent industry developments.

Thyrogen and Biosimilar Market Report Scope & Segmentation

REPORT COVERAGE DETAILS
Market Size Value In USD 527.6 Million in 2026
Market Size Value By USD 1901.53 Million by 2035
Growth Rate CAGR of 15.31% from 2026-2035
Forecast Period 2026 - 2035
Base Year 2025
Historical Data Available Yes
Regional Scope Global
Segments Covered
By Type Brand | Biosimilar
By Application Hospital | Pharmacy | Other

Frequently Asked Questions

In 2026, the Thyrogen and Biosimilar Market size stood at USD 527.6 Million.

The global Thyrogen and Biosimilar Market is expected to reach USD 1901.53 Million by 2035.

The global Thyrogen and Biosimilar Market is projected to expand at a CAGR of 15.31% by 2035.

Sanofi, Sato Pharmaceutical

OUR
CLIENTS

Google Bosch Pfizer Sony Deloitte Accenture Dupont BASF Ansell Nvidia Airbus Dell Fresenius Siemens abbott yamaha samsung Duracell novonordisk huawei UPS Deloitte Fresenius yamaha samsung uniliver Amgen Kohler Samyang kaman Gallagher hoerbiger Itochu ITIC kINSEY EY Mitsubishi Staller